 DURHAM, N.C., March 30, 2021 GLOBE NEWSWIRE -- Bioventus Inc. Nasdaq: BVS Bioventus or the Company, a global leader in innovations for active healing, has acquired Bioness, Inc. Bioness, a global leader in neuromodulation and rehabilitation medical devices through its innovative peripheral nerve stimulation PNS therapy and premium rehabilitation solutions, for 45 million in up-front consideration, with up to 65 million of contingent consideration related to the achievement of certain key milestones. The acquisition includes the entire portfolio of Bioness products as well as its research and development pipeline. Under the merger agreement, Bioness has become a wholly-owned subsidiary of Bioventus, and all Bioness employees have become employees of Bioventus. The up-front consideration is being funded exclusively through the use of cash on hand. 